Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 7/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12648575 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4ESR1 | |
| SCHEMBL30938556 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4ESR1 | |
| SCHEMBL29367546 | 0.82 | MEN1 (0.70) | MEN1KMT2ACYP1A2CYP3A4ESR1 | |
| SCHEMBL25362682 | 0.81 | MEN1 (0.68) | MEN1KMT2ACYP1A2CYP3A4CA12 | |
| SCHEMBL8615977 | 0.81 | MEN1 (0.68) | MEN1KMT2ACYP1A2CYP3A4CA12 | |
| SCHEMBL9004077 | 0.78 | MEN1 (0.64) | MEN1KMT2ACYP1A2CYP3A4HSD17B10 | |
| SCHEMBL9004079 | 0.78 | MEN1 (0.64) | MEN1KMT2ACYP1A2CYP3A4HSD17B10 | |
| SCHEMBL10596148 | 0.77 | MEN1 (0.62) | MEN1KMT2ACYP1A2CYP3A4ESR1 | |
| SCHEMBL11018237 | 0.77 | MEN1 (0.62) | MEN1KMT2ACYP1A2CYP3A4ESR1 | |
| SCHEMBL1159922 | 0.75 | MEN1 (0.59) | MEN1KMT2ACYP1A2CYP3A4GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120049510-A | Coordinated operation optimization method and system for multi-type pumping and storage units | 国家电网有限公司华中分部 | 2025-05-27 | — | — | CN | claimed |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-04-24 | — | — | US | claimed |
| US-12156879-B2 | Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy | UNIVERSITY OF CONNECTICUT (US) | 2024-12-03 | — | — | US | claimed |
| WO-2024063818-A9 | METHODS AND COMPOSITIONS FOR GENERATING OLIGODENDROCYTE PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023150534-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-08-10 | — | — | WO | claimed |
| CN-115906456-A | Hydrogen-containing energy IES scheduling optimization model considering response uncertainty of demand side | 国网甘肃省电力公司武威供电公司 | 2023-04-04 | — | — | CN | claimed |
| CN-106849176-B | Modeling method of random sequence optimization model considering wind power uncertainty | 国网江苏省电力公司南京供电公司 | 2023-02-17 | — | — | CN | claimed |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| CN-120617206-B | Ergosterol-loaded engineering exosome dual-drug-loading system and preparation method and application thereof | 无锡市第二人民医院 | 2026-05-15 | — | — | CN | disclosed |
| CN-120617206-B | Ergosterol-loaded engineering exosome dual-drug-loading system and preparation method and application thereof | 无锡市第二人民医院 | 2026-05-15 | — | — | CN | disclosed |
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| CN-121177271-A | Application of mGluR5 agonist CHPG in preparation of antithrombotic drugs | 贵州医科大学 | 2025-12-23 | — | — | CN | disclosed |
| CN-121177271-A | Application of mGluR5 agonist CHPG in preparation of antithrombotic drugs | 贵州医科大学 | 2025-12-23 | — | — | CN | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| CN-115379847-A | Synthetic peptides for modulating metabotropic glutamate receptor 5 | 拉托科公司 | 2022-11-22 | — | — | CN | disclosed |
| WO-2022159629-A1 | COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION- RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20220226331-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE, INC. | 2022-07-21 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220056009-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | NXERA PHARMA UK LIMITED (GB) | 2022-02-24 | — | — | US | disclosed |
| US-20220031778-A1 | METHOD OF REDUCING NEURONAL MICROTUBULE BINDING PROTEIN TAU (TAU) LEVELS | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12156879-B2 | Combining BACE1 inhibitors with mGluR agonists for Alzheimer's disease therapy | BACE1, PSEN1, PSEN2 | MEN1 3300/4885KMT2A 2096/4885CYP1A2 4795/4885 |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | MEN1 4793/4885KMT2A 1265/4885CYP1A2 2512/4885 |
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | CASR, ORAI1, TRPC3 | MEN1 3878/4885KMT2A 4664/4885CYP1A2 3673/4885 |
| US-20250129045-A1 | SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF | PIM3, PIM1, PIM2 | MEN1 3315/4885KMT2A 2281/4885CYP1A2 4861/4885 |
| US-20220056009-A1 | 4-(3-CYANOPHENYL)-6-PYRIDINYLPYRIMIDINE MGLU5 MODULATORS | GRM5, GRM6, GRM2 | MEN1 4742/4885KMT2A 1402/4885CYP1A2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.